Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (vol 10, pg 583, 2015)

Despierre Evelyn; Vergote Ignace; Anderson Ryan; Coens Corneel; Katsaros Dionyssios; Hirsch Fred R.; Boeckx Bram; Varella-Garcia Marileila; Ferrero Annamaria; Ray-Coquard Isabelle; Green John A.; Steer Christopher; Berns Els M. J. J.; Casado Antonio; Lambrechts Diether; Jimeno Antonio

首页> 外文期刊>Targeted oncology >Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (vol 10, pg 583, 2015)

【24h】

Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (vol 10, pg 583, 2015)

机译：表皮生长因子受体（EGFR）途径生物标志物在厄洛替尼的III期随机试验中与在无一线铂类化学疗法后无疾病进展迹象的卵巢癌患者中观察到的比较（第10卷，第583页，2015年）

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Targeted oncology 》 |2016年第3期| 共1页
作者
Despierre Evelyn; Vergote Ignace; Anderson Ryan; Coens Corneel; Katsaros Dionyssios; Hirsch Fred R.; Boeckx Bram; Varella-Garcia Marileila; Ferrero Annamaria; Ray-Coquard Isabelle; Green John A.; Steer Christopher; Berns Els M. J. J.; Casado Antonio; Lambrechts Diether; Jimeno Antonio;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学 ;
关键词

相似文献

外文文献
中文文献
专利

1. Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (vol 10, pg 583, 2015) [J] . Despierre Evelyn, Vergote Ignace, Anderson Ryan, Targeted oncology . 2016 ,第3期

机译：表皮生长因子受体（EGFR）途径生物标志物在厄洛替尼的III期随机试验中与在无一线铂类化学疗法后无疾病进展迹象的卵巢癌患者中观察到的比较（第10卷，第583页，2015年）
2. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study. [J] . Ignace B Vergote, Antonio Jimeno, Florence Joly, Journal of Clinical Oncology . 2014 ,第4期

机译：欧洲癌患者患者欧洛替尼对患者患者的随机期III研究 - 卵巢癌化疗患者：欧洲癌症 - 妇科癌症组的研究和治疗组织，妇科癌症杂交研究。
3. The Role of Smoking Status on the Progression-Free Survival of Non-Small Cell Lung Cancer Patients Harboring Activating Epidermal Growth Factor Receptor (EGFR) Mutations Receiving First-Line EGFR Tyrosine Kinase Inhibitor Versus Platinum Doublet Chemotherapy: A Meta-Analysis of Prospective Randomized Trials [J] . Hasegawa Yoshikazu, Ando Masahiko, Maemondo Makoto, The oncologist . 2015 ,第3期

机译：吸烟状态在非活化小细胞肺癌患者无进展生存中的作用，该患者具有接受一线EGFR酪氨酸激酶抑制剂与铂类双重治疗的活化表皮生长因子受体（EGFR）突变：前瞻性随机试验的荟萃分析。
4. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
5. Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy [O] . Evelyn Despierre, Ignace Vergote, Ryan Anderson, -1

机译：表皮生长因子受体（EGFR）通路生物标志物在厄洛替尼的III期随机试验与观察的卵巢癌患者中无一线铂类化学疗法后疾病进展的证据
6. Erratum to: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy [O] . Despierre, Evelyn, Vergote, Ignace, Anderson, Ryan, 2016

机译：勘误至：厄洛替尼的III期随机临床试验与表皮生长因子受体（EGFR）通路生物标志物对比在没有一线铂类化学疗法一线治疗的卵巢癌患者中的观察

Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (vol 10, pg 583, 2015)

著录项

相似文献

相关主题

期刊订阅